Vanguard Investments Australia
NAMS icon

Vanguard Investments Australia’s NewAmsterdam Pharma NAMS Stock Holding History

Vanguard Investments Australia’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$535K Buy
15,774
+5,747
+57% +$189K ﹤0.01% 1628
2026
Q1 		$321K Buy
+10,027
New +$327K ﹤0.01% 1806

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Vanguard Investments Australia's NAMS Position: Q2 2026 in Review

Vanguard Investments Australia increased its NewAmsterdam Pharma (NAMS) stake by 57% in Q2 2026, buying an estimated $189K and bringing the position to 15,774 shares worth $535K. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

Vanguard Investments Australia first reported a position in NAMS in Q1 2026 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Vanguard Investments Australia held 15,774 shares of NewAmsterdam Pharma worth $535K as of Q2 2026.
  • Vanguard Investments Australia bought 5,747 NewAmsterdam Pharma shares in Q2 2026, an estimated $189K.
  • NewAmsterdam Pharma made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1628 holding.
  • Vanguard Investments Australia first reported a position in NewAmsterdam Pharma in Q1 2026 and has held it in 2 quarters since.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.